TMO

$542.36

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 6.66% trendline growth.
Want to create your own valuation? Create a free account.
$522.94

With 20% Margin of Safety (MoS):

$418.35
-22.86% downside
Capital Efficiency
Average Quarterly ROIC
2.44%
Cost of Capital (estimated)9%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.
Fundamental Score
23
BearishWeighted across 6 signals
DCF Discount
22.9% premium to price
12
FCF Yield
4.6% trailing FCF yield
65
ROIC vs WACC
ROIC 2.4% vs WACC 9.0% (0.3x)
14
Net Debt / FCF
3.1x net debt to FCF
0
Buybacks
Share count shrinking
80
FCF CAGR (5Y)
-0.4% 5Y FCF CAGR (adjusted)
0
Strengths: Buybacks. Concerns: DCF Discount, ROIC vs WACC.
Narrative Score
77
Improving
Weighted across 6 recent drivers · Last 30 daysVs 6-Month Baseline: High (88th pct)
Trend: StableConfidence: 89%Updated: 5h ago
Sources: 99 (News 89 · Analyst 10)
Drivers
32 news sentiment+1.8
52 regulatory scrutiny+0.5
Margin pressure+0.3
3 earnings beat+0.1
Restructuring-0.1
3 analyst upgrades+0.0
Other Metrics
P/E30.4
Profit Margin15.1%
Owner Earnings$11.02b
One Dollar Premise10.00%
Debt/Equity1.02
Current Ratio1.77
PEG12.246
Free Cash Flow (in millions)
20062007200820092010201120122013201420152016201720182019202020212022202320242025
$482$1,659$1,685$1,867$1,763$1,958$2,355$2,293$3,047$3,240$3,601$4,513$5,301$5,899$9,763$12,066$11,397$9,885$10,067$9,343
How Intrinziq Estimates Fair Value

Intrinziq estimates Thermo Fisher Scientific Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Thermo Fisher Scientific Inc.Healthcare

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.